Innate and adaptive immune receptors (Broad engagement)

The term Innate and adaptive immune receptors – broad, non-specific engagement describes a therapeutic strategy or mechanism of action rather than a single, discrete molecular target. It involves the simultaneous modulation of various receptor families, including pattern recognition receptors (PRRs) like Toll-like receptors (TLRs) on innate cells and antigen-specific receptors on T and B lymphocytes (Source: Nature Reviews Immunology). This broad engagement is typically intended to jump-start a dormant immune response against pathogens or tumors, or conversely, to provide systemic immunomodulation in the case of autoimmune or inflammatory disorders (Source: StatPearls). Common examples of agents that function through this broad engagement include vaccine adjuvants, which non-specifically prime the immune system, and intravenous immunoglobulin (IVIG), which interacts with a wide array of Fc receptors and circulating antibodies (Source: PubMed/NIH). Due to the lack of a specific protein identifier, this entry is categorized as a broad therapeutic approach rather than a canonical drug target. It is often used in clinical literature to describe the pleiotropic effects of complex biologics or multi-target immunotherapies.

Other names

Broad immunomodulatorsPan-immune receptor engagementSystemic immune activatorsNon-specific immune stimulantsImmune response modifiers

Broadly modulates the immune system by engaging multiple pattern recognition receptors (PRRs) and signaling pathways across innate and adaptive immune cells to enhance or suppress immune activity (Source: NIH/NCBI, PubMed).